The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — including colorectal, gastric, kidney and liver cancer — is also on the rise, though cancer among patients under 50 is still relatively rare overall, Dr. Partridge said.

Trends in breast, prostate and lung cancer are shifting who is most at-risk.

It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.